1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

Portfolio Includes Psychedelic And Non-Psychedelic Drugs

 
• By Alaric DeArment

The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.

Business, Technology, Internet and network concept. Young businessman working on a virtual screen of the future and sees the inscription: venture capital
ATAI Life Sciences raised $125m to fund preclinical and clinical mental health programs. • Source: Shutterstock

ATAI Life Sciences AG said on 23 November that it closed a $125m series C funding round that will help it advance its slate of preclinical and clinical mental health programs, which include several psychedelic programs – ranging from a psilocybin-derived drug to the hallucinogenic compound in ayahuasca. Management told Scrip that Johnson & Johnson’s development of ketamine as Spravato helped clear the way for its own programs.

The series C funding will support preclinical and clinical mental health programs, as well as expand ATAI’s pipeline of drug candidates and advance its platform technologies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from R&D